TARA
Protara Therapeutics, Inc.
$4.27
+0.19 (+4.66%)
At close · Jul 7
Market Cap
$236.06M
Shares
56,204,237
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.27
Open$4.09
Day$4.03–4.49
52W$2.80–7.82
Avg vol 30d792K
Short int4.5M · 7.9% float · 6.6d
Short vol62%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.1 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
−6%
below
RSI (14)
52
neutral
MACD trend
Positive
52-week position
29%
mid-range
Momentum
relative strength
1-month return
+3%
trailing
6-month return
−19%
trailing
YTD return
−20%
this year
Relative strength
−26%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
2 of 114 funds reported for Jun 30 · net +226 sh shares · +1 new
Insider flow
Distributing
Net -$882.2K over 90 days · 100% sells
Short interest
Falling
7.95% of float · ▼ -24.2% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
114 holders — near 3-yr high, broad support
Squeeze score
57
elevated · 0–100
Fundamentals
EPS growth
+38%
Y/Y
Free cash flow
$-56.5M
Balance sheet
$49.7M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 14, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
29%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
2 of 114 funds reported for Jun 30 · net +226 sh shares · +1 new
Insider flow
Distributing
Net -$882.2K over 90 days · 100% sells
Short interest
Falling
7.95% of float · ▼ -24.2% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
114 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $4 · 29%
52-wk high $8
vs 200-day avg -20%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TARA
this stock
Protara Therapeutics, Inc.
|
$236.06M | -19.9% | — | — | 7.9% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TARA | +2.6% | +2.6% | -18.5% | +11.8% | -19.9% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +1.7% | +1.3% | -26.1% | +11.7% | -29.5% |